ライフサイエンスコーパス: pyridoxine

1 id, biotin, folate, riboflavin, thiamin, and pyridoxine).

2 grade 2 or higher HFS in patients receiving pyridoxine.

3 symptoms that are treatable with PLP and/or pyridoxine.

4 ptom-free on occasional phlebotomy and daily pyridoxine.

5 tagonistic effect on the utilization of free pyridoxine.

6 e and E4P dehydrogenases are auxotrophic for pyridoxine.

7 r 3 days with concomitant metoclopramide and pyridoxine.

8 y combining it with the vitamin B6 precursor pyridoxine.

9 atients who responded and did not respond to pyridoxine.

10 n seizures that to respond to treatment with pyridoxine.

11 es was observed after 28 d of treatment with pyridoxine.

12 the NADPH-mediated reduction of pyridoxal to pyridoxine.

13 quitin deficiency and are then responsive to pyridoxine.

14 ve seizures, but who responded clinically to pyridoxine.

15 formulation (n = 1827), containing 25 mg of pyridoxine, 0.4 mg of cobalamin, and 2.5 mg of folic aci

16 We set out to turn pyridoxine (1a) into a catalytic chain-breaking and hydr

17 tients were randomized to receive concurrent pyridoxine (200 mg) or placebo daily for a maximum of 8

18 They were given pyridoxine (350 mg/kg, i.p.) on 2 successive days (0 and

19 ng studies of the nutritional utilization of pyridoxine 5'-beta-D-glucoside, a major form of vitamin

20 B6 include pyridoxamine 5'-phosphate (PMP), pyridoxine 5'-phosphate (PNP), and the corresponding non

21 that leads productively to the formation of pyridoxine 5'-phosphate (PNP).

22 BS before and after a 30 min incubation with pyridoxine 5'-phosphate (PNP).

23 due to an approximately 192-fold decrease in pyridoxine 5'-phosphate affinity and an approximately 4.

24 ridoxal 5'-phosphate by the FMN oxidation of pyridoxine 5'-phosphate forming FMNH(2) and H(2)O(2).

25 Pyridoxine 5'-phosphate hydrolase activity (pH 10) in cu

26 sistent significant change in pyridoxine and pyridoxine 5'-phosphate levels.

27 Mutations in pyridoxine 5'-phosphate oxidase are known to cause neona

28 Pyridoxine 5'-phosphate oxidase catalyzes the oxidation

29 Escherichia coli pyridoxine 5'-phosphate oxidase catalyzes the terminal s

30 e shown that in addition to the active site, pyridoxine 5'-phosphate oxidase contains a non-catalytic

31 orm of the Arabidopsis epimerase lacking the pyridoxine 5'-phosphate oxidase domain.

32 The crystal structure of pyridoxine 5'-phosphate oxidase from E. coli with one or

33 nding the pathophysiological consequences of pyridoxine 5'-phosphate oxidase mutations.

34 n with a combination of pyridoxal kinase and pyridoxine 5'-phosphate oxidase.

35 duct inhibition of both pyridoxal kinase and pyridoxine 5'-phosphate oxidase.

36 being fused to the vitamin B6 salvage enzyme pyridoxine 5'-phosphate oxidase.

37 We report the 1.96 A crystal structure of pyridoxine 5'-phosphate synthase (PdxJ) in complex with

38 phosphate oxidase catalyzes the oxidation of pyridoxine 5'-phosphate to pyridoxal 5'-phosphate, the a

39 icipate in formation of the pyridine ring of pyridoxine 5'-phosphate.

40 yridoxamine) kinase (SOS4) and pyridoxamine (pyridoxine) 5' phosphate oxidase (PDX3), have been ident

41 In particular, pyridoxine- 5'-phosphate oxidase (PNPO), the rate-limiti

42 in the mammalian nutritional utilization of pyridoxine-5'-beta-D-glucoside (PNG) is the intestinal h

43 ulation (n = 1853), containing 200 microg of pyridoxine, 6 microg of cobalamin and 20 microg of folic

44 Beta-Glucosides of pyridoxine (a) are prevalent in plant-derived foods, (b)

45 The cyclic pyridoxine-alpha4, 5-monophosphate, compound 2 (MRS 2219

46 ral regions, where amino acids, tocopherols, pyridoxine and 4-aminobenzoic acid show intense emission

47 commend consideration of treatment with both pyridoxine and folinic acid for patients with alpha-AASA

48 catalyses the phosphorylation of pyridoxal, pyridoxine and pyridoxamine to their 5' phosphates and p

49 tion as a PL kinase, in vitro application of pyridoxine and pyridoxamine, but not PL, partially rescu

50 here was no consistent significant change in pyridoxine and pyridoxine 5'-phosphate levels.

51 le, phenobarbital, chlorpheniramine maleate, pyridoxine and riboflavin.

52 cts of thiamin, especially in medium lacking pyridoxine and with high sugar concentrations.

53 aining 0.45 mg vitamin B-6 (2.66 micromol as pyridoxine) and 30 micromol carnitine for 92 d.

54 involved in the biosynthesis of vitamins B6 (pyridoxine) and B1 (thiamin).

55 es and the intake of folic acid, vitamin B6 (pyridoxine), and vitamin B12 (cobalamin).

56 roup vitamins alone (1 mg folic acid, 7.2 mg pyridoxine, and 0.02 mg cyanocobalamin), antioxidant vit

57 exercise their primary functions in serine, pyridoxine, and histidine biosynthesis, they also have c

58 utrient metabolism; and folate, vitamin B12, pyridoxine, and riboflavin play important roles in the r

59 ry high intakes of vitamins A and D, niacin, pyridoxine, and selenium have produced adverse effects.

60 efficiency with pyridoxal, pyridoxamine and pyridoxine, and that ginkgotoxin is an effective pseudo

61 y Allowances of thiamin, riboflavin, niacin, pyridoxine, and vitamin B-12.

62 s of nausea and emesis of pregnancy, ginger, pyridoxine, antihistamines, and metoclopramide were asso

63 r HFS occurred in 33 patients (31.4%) in the pyridoxine arm vs 39 patients (37.1%) in the placebo arm

64 from neuropathy induced by intoxication with pyridoxine assessed by electrophysiological (foot sensor

65 rmed by complementation of two C. nicotianae pyridoxine auxotrophs not mutant in PDX1.

66 lacement of PDX2 in C. nicotianae results in pyridoxine auxotrophy.

67 f B vitamins (thiamin B(1), riboflavin B(2), pyridoxine B(6), biotin B(7), and cobalamin B(12)) were

68 m NSCLC by the combined regimen of CDDP plus pyridoxine became resistant against subcutaneous rechall

69 at hydrolyzed aryl beta-D-glycosides but not pyridoxine beta-D-glucoside.

70 oside hydrolase, that efficiently hydrolyzed pyridoxine beta-D-glucoside.

71 d specificity beta-glucosidase 1460-fold and pyridoxine-beta-D-glucoside hydrolase 36,500-fold.

72 f lysosomal acid beta-glucosidase, inhibited pyridoxine-beta-D-glucoside hydrolase but not broad spec

73 Purified pyridoxine-beta-D-glucoside hydrolase did not hydrolyze

74 Pyridoxine-beta-D-glucoside hydrolase exhibited a pH opt

75 ound a previously unknown enzyme, designated pyridoxine-beta-D-glucoside hydrolase, that efficiently

76 nt differences were observed in the level of pyridoxine between the meat and vegetable-based varietie

77 that organisms encode either SOR1 or E. coli pyridoxine biosynthesis genes, but not both, suggesting

78 Although pyridoxine biosynthesis has been thoroughly examined in

79 there are two divergent pathways for de novo pyridoxine biosynthesis in nature.

80 wth, demonstrating that PDX1 is required for pyridoxine biosynthesis in planta.

81 ion of a second gene in the newly identified pyridoxine biosynthesis pathway of archaebacteria, some

82 e vitamin B6 biosynthesis protein machinery, PYRIDOXINE BIOSYNTHESIS PROTEIN1.

83 The role of PDX2 in pyridoxine biosynthesis was confirmed by complementation

84 encoding an enzyme specifically required for pyridoxine biosynthesis.

85 as enabled us to define a second pathway for pyridoxine biosynthesis.

86 bacteria evolved with different pathways for pyridoxine biosynthesis?

87 Gene expression, PYRIDOXINE BIOSYNTHESIS1 (PDX1) accumulation, and leaf m

88 Some bacteria utilize the pdx pyridoxine biosynthetic pathway defined in Escherichia c

89 Supplementation of pyridoxine but not pyridoxal in the growth medium can pa

90 zures that did not respond to treatment with pyridoxine but responded to treatment with pyridoxal 5'-

91 e yeast were grown in high concentrations of pyridoxine, but a severe phenotype when grown in low con

92 The increase in nicotinamide and decrease in pyridoxine by curing salts and the decrease in both vita

93 hoxazole plus at least 12 weeks of isoniazid-pyridoxine (coformulated with trimethoprim-sulfamethoxaz

94 The novel pyridoxine compounds were found to inhibit azo-initiated

95 Reducing the pyridoxine content of the culture medium significantly i

96 ancer Centre Singapore assessed whether oral pyridoxine could prevent the onset of grade 2 or higher

97 The chalcogen-containing pyridoxines could also mimic the action of the glutathio

98 Pyridoxine dependency is an uncommon but important cause

99 series suggested that clinical diagnosis of pyridoxine dependent epilepsy can be challenging because

100 Pyridoxine dependent epilepsy is a treatable condition w

101 Pyridoxine dependent epilepsy is diagnosed clinically bu

102 wn clinical disorders of GABA metabolism are pyridoxine dependent epilepsy, GABA-transaminase deficie

103 at mutations in the human ALDH7A1 gene cause pyridoxine-dependent and folic acid-responsive seizures.

104 lities has been reported in individuals with pyridoxine-dependent epilepsy (PDE).

105 patients with suspected or clinically proven pyridoxine-dependent epilepsy and to characterize furthe

106 Folinic acid-responsive seizures and pyridoxine-dependent epilepsy are two treatable causes o

107 o children from a consanguineous family with pyridoxine-dependent epilepsy revealed a homozygous nons

108 Pyridoxine-dependent epilepsy was recently shown to be d

109 seizures are identical to the major form of pyridoxine-dependent epilepsy.

110 We show here that children with pyridoxine-dependent seizures (PDS) have mutations in th

111 rve as a diagnostic marker for patients with pyridoxine-dependent seizures.

112 The most lipid-soluble pyridoxine derivative 20c was regenerable and could inhi

113 In vitro, CDDP and pyridoxine did not only cause synergistic killing of NSC

114 Pyridoxine did not significantly prevent or delay the on

115 other PN derivative that was identified as a pyridoxine disaccharide.

116 vere symptoms, 1 RCT (n = 60) suggested that pyridoxine-doxylamine combination taken preemptively red

117 tamines, metoclopramide (for mild symptoms), pyridoxine-doxylamine, and ondansetron (for moderate sym

118 For moderate symptoms, pyridoxine-doxylamine, promethazine, and metoclopramide

119 CDDP and pyridoxine exhibited hyperadditive therapeutic effects.

120 ms of the Reference Nutrient Intake (RNI) of pyridoxine for 6-9 months old infants, the complementary

121 timated total daily intake of riboflavin and pyridoxine from the consumption of commercial complement

122 the organisms with homologues to the E. coli pyridoxine genes, but are found in the same archaebacter

123 Pyridoxine given in large doses is thought to destroy se

124 the activity and its consequences regarding pyridoxine glucoside bioavailability are in progress.

125 ay comprising pyridoxine synthase (PDX1) and pyridoxine glutaminase (PDX2).

126 out in 1.0x10(-4)molkg(-1) thiamine HCl and pyridoxine HCl solutions.

127 0.25 and 0.35)molkg(-1) thiamine HCl(aq) and pyridoxine HCl(aq) solutions over temperature range (288

128 in, niacinamide, d-calcium pantothenate, and pyridoxine HCl; 50 microg each of d-biotin and cyanocoba

129 in plasma in 10 men receiving a low (0.4 mg pyridoxine.HCl/d) or high (200 mg pyridoxine.HCl/d) vita

130 ow (0.4 mg pyridoxine.HCl/d) or high (200 mg pyridoxine.HCl/d) vitamin B-6 intake for 6 wk, in 10 hea

131 and after 28 d of supplementation with 10 mg pyridoxine hydrochloric acid/d.

132 le containing 40 mg of folic acid, 100 mg of pyridoxine hydrochloride (vitamin B6), and 2 mg of cyano

133 olic transformations of [3,4-14C] and [3H]C6-pyridoxine hydrochloride by tumor-bearing rats and tumor

134 were randomized to isoniazid, 300 mg/d, with pyridoxine hydrochloride for 12 months (n = 792) or rifa

135 before and after daily treatment with 40 mg pyridoxine hydrochloride.

136 andgrip before and after a local infusion of pyridoxine (i.e. vitamin B(6)) into the 'isolated' circu

137 lin, levetiracetam), hypothermia, magnesium, pyridoxine, immunotherapy, ketogenic diet, emergency neu

138 ts, suggesting a previously unknown role for pyridoxine in active oxygen resistance.

139 quantitative determination of riboflavin and pyridoxine in eight different complementary infant meal

140 ntiquitin deficiency and a clinical trial of pyridoxine in infants and children with epilepsy across

141 ed remarkable concentrations of thiamine and pyridoxine in pistachios (57%, 79% of the recommended da

142 utative synergistic interaction of CDDP with pyridoxine in the treatment of an orthotopic mouse model

143 NSCLC cells treated with CDDP plus pyridoxine in vitro elicited a protective anticancer imm

144 s respond to pyridoxal phosphate rather than pyridoxine, including a rare form of neonatal epileptic

145 This study examined the effects of pyridoxine-induced somatosensory loss on automatic postu

146 Pyridoxine is converted into a P2-purinoceptor antagonis

147 We also found that pyridoxine is destroyed in the presence of singlet oxyge

148 energy drinks, such as taurine, niacin, and pyridoxine, is less well defined.

149 imics of the glutathione peroxidase enzymes, pyridoxine-like diselenides 6 and 11, carrying a 6-bromo

150 Thiamine, riboflavin, pyridoxine, lutein, zeaxanthin, beta-carotene and alpha-

151 with multisystem pathology, the response to pyridoxine may not be instant and obvious; and (iii) str

152 by high doses of folic acid, cobalamin, and pyridoxine may reduce progression of structural brain ch

153 ely, a component of Bendectin (most probably pyridoxine) may be important for normal heart developmen

154 that the combined regimen of cisplatin plus pyridoxine mediates immune-dependent antineoplastic effe

155 MC-1, a naturally occurring pyridoxine metabolite and purinergic receptor antagonist

156 symmetric molecular constructs, in which two pyridoxine moieties are connected via sulfur-containing

157 starting under 3 months of age responding to pyridoxine (n = 8).

158 to PLP supplementation, consistent with the pyridoxine-nonresponsive phenotype of the T257M mutation

159 la mutants defective for para-aminobenzoate, pyridoxine or l-threonine biosynthesis exhibit substanti

160 ency and severity of seizures in response to pyridoxine or pyridoxal 5'-phosphate.

161 Supplementation of the growth media with pyridoxine or reintroduction of the wild-type PDX1 gene

162 ther pyridoxal (PL) or its related vitamers, pyridoxine (PN) and pyridoxamine (PM).

163 Vitamin B6 in the form of pyridoxine (PN) is one of the most widespread pharmacolo

164 is of its beta-glucosidic bond that releases pyridoxine (PN).

165 pdrK encodes a pyridoxine (PN)/pyridoxal (PL)/pyridoxamine (PM) kinase

166 n of two major components of vitamin B6 i.e. pyridoxine (Py) and pyridoxal-5'-phosphate (PLP) using t

167 e reannotated ThiD, and B. subtilis ThiD has pyridoxine, pyridoxal, and pyridoxamine kinase activity

168 erized, however only two enzymes, pyridoxal (pyridoxine, pyridoxamine) kinase (SOS4) and pyridoxamine

169 This mutant had higher levels of pyridoxine, pyridoxamine, and pyridoxal 5'-phosphate tha

170 dinium derivatives (pyridinoline, desmosine, pyridoxine, pyridoxamine, pyridoxal, pyridoxal-5'-phosph

171 and SALT OVERLY SENSITIVE4 (SOS4), encoding pyridoxine/pyridoxamine 5'-phosphate oxidase and pyridox

172 We also present data showing that pyridoxine quenches singlet oxygen at a rate comparable

173 190V mutant was identified in a patient with pyridoxine-refractory X-linked sideroblastic anemia, our

174 contain the minimum levels of riboflavin and pyridoxine required for the labelling declaration of the

175 omologs map to the region occupied by pdx-1 (pyridoxine requiring), a gene that has been known for se

176 In this study, pyridoxine-requiring mutants of N. crassa were found to

177 the G797A mutation is an important cause of pyridoxine-responsive CBS deficiency and demonstrate the

178 Five of the seven patients classified as pyridoxine-responsive contain the newly identified point

179 t sequencing of 29 unrelated indivduals with pyridoxine-responsive epilepsy identified four additiona

180 All probands were clinically pyridoxine-responsive.

181 It is possible that pyridoxine responsiveness in PNPO deficiency is affected

182 obands suggest that iron overload suppresses pyridoxine responsiveness.

183 ant lacking the PROSC homolog (DeltaYggS) is pyridoxine sensitive; complementation with human PROSC r

184 tic trials of pyridoxal phosphate as well as pyridoxine should be considered early in the course of t

185 s, anti-epileptic drugs, magnesium infusion, pyridoxine, steroids and immunotherapy, ketogenic diet,

186 PLP, having been resistant to treatment with pyridoxine, suggesting a defect of pyridox(am)ine 5'-pho

187 hese malformations persist despite postnatal pyridoxine supplementation and likely contribute to neur

188 ndicate the value of combined phlebotomy and pyridoxine supplementation in the management of XLSA pro

189 Pyridoxine supplementation increased the mean +/- SD pla

190 d in higher hemoglobin concentrations during pyridoxine supplementation.

191 using a relatively simple pathway comprising pyridoxine synthase (PDX1) and pyridoxine glutaminase (P

192 In this study, an Arabidopsis pyridoxine synthase gene PDX1 was characterized and its

193 e the vitamin de novo employing two enzymes, pyridoxine synthase1 (PDX1) and PDX2.

194 the discovery that most organisms contain a pyridoxine synthesis gene not found in E. coli.

195 t shows no homology to previously identified pyridoxine synthesis genes identified in Escherichia col

196 tory occlusion were significantly less after pyridoxine than they were before.

197 menting the diet of rats with tryptophan and pyridoxine; the elevated brain serotonin levels had beha

198 Pyridoxine therapy had no effect in the proband, but in

199 with these mutations should be responsive to pyridoxine therapy.

200 was a worsening of symptoms on changing from pyridoxine to pyridoxal 5'-phosphate.

201 Pyridoxine toxicity was manifest as deficits in simple a

202 lectrophysiological sequelae associated with pyridoxine toxicity.

203 ; 5-20 mg . kg-1 . d-1, s.c.) during chronic pyridoxine treatment largely attenuated the behavioral a

204 We aimed to assess the effect of pyridoxine treatment on B-6 vitamer and inflammatory mar

205 ECA reduced oxalate accumulation, similar to pyridoxine treatment that works in a small subset of PH1

206 nts diagnosed with CBS deficiency respond to pyridoxine treatment with a significant lowering of tHcy

207 rkers were preserved or even increased after pyridoxine treatment.

208 d and patient cohorts; however, vitamin B-6 (pyridoxine) treatment has mostly failed to improve infla

209 e development of a therapeutical approach to pyridoxine unresponsive homocystinuria.

210 Pyridoxine (vitamin B6) is a cofactor required by numero

211 served proteins that have been implicated in pyridoxine (vitamin B6) metabolism in the filamentous fu

212 adult rats for 2-3 weeks with high doses of pyridoxine (vitamin B6) produced a profound propriocepti

213 We show that SOR1 is essential in pyridoxine (vitamin B6) synthesis in C. nicotianae and A

214 mine (dropped from the formulation in 1976), pyridoxine (vitamin B6)), was associated with a lower ri

215 ed into a single fixed-dose pill, along with pyridoxine (vitamin B6), that would be taken once per da

216 uced with pharmacologic doses of folic acid, pyridoxine, vitamin B12, or betaine, but further researc

217 Glycosylated forms of pyridoxine, vitamin D, niacin, pantothenate, and ribofla

218 grade 2 or greater HFS in patients receiving pyridoxine vs placebo and to identify biomarkers predict

219 Moreover, treatment with both DECA and pyridoxine was additive in reducing oxalate levels.

220 ety: i.e. a CH2OH group at the 4-position in pyridoxine was either condensed as a cyclic phosphate or

221 The intake of both riboflavin and pyridoxine was estimated to be mainly derived from the c

222 corresponding organic product (pyridoxal and pyridoxine) was -0.03 +/- 0.09.